Évolution de la demande des examens de médecine nucléaire pour cancer de la prostate depuis l’enregistrement de la fluorocholine (18F) : analyse sur deux ans à l’hôpital Tenon

Balogova, Sona; Kobetz, A.; Huchet, Virginie; Michaud, Laure; Kerrou, Khaldoun; Paycha, F.; Nataf, Valérie; Idir, Z.; Hodolič, Marina; Vereb, Marika; Montravers, F.; Talbot, Jean‐Noël

doi:10.1016/j.mednuc.2012.04.004

Cited by 2 publications

(4 citation statements)

References 32 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The initial shift from BS to bone PET/CT with fluoride(18F), which has been observed in Paris1, is in agreement with the results of the comparative study of Even-Sapir et al ., in 44 patients with a high-risk prostate cancer 3. Fluoride(18F) PET/CT was statistically more sensitive and more specific than planar BS or bone SPECT (p < 0.05).…”

Section: Discussionsupporting

confidence: 89%

“…As its first result, this dual centre study confirms, in two independent nuclear medicine centres, the rapid rise in the demand for FCH PET/CT, as soon as FCH was registered. 1 At the same time, there was a marked decline in the prescription of BS in patients with prostate cancer. This shift was associated with a rise of the total number of prostate cancer patients referred for nuclear medicine examinations.…”

Section: Discussionmentioning

confidence: 99%

“…We published a survey that showed the shift in the prescription of nuclear medicine imaging favouring FCH PET/CT at Hospital Tenon in Paris, after its registration. 1 All those radiopharmaceuticals have marketing authorisation and are available for the routine use also in five other EU member states: Austria, France, Germany, Poland and Slovenia.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Consequence of the introduction of routine FCH PET/CT imaging for patients with prostate cancer: a dual centre survey

Hodolič¹,

Michaud²,

Huchet³

et al. 2014

Radiology and Oncology

View full text Add to dashboard Cite

BackgroundFluorocholine(18F) (FCH) was introduced at the beginning of April 2010 in France, Slovenia and three other EU member states for the localisation of bone metastases of prostate cancer with PET. The aim of the study was to compare the evolution of diagnostic imaging in patients with prostate cancer using a new radiopharmaceutical FCH, observed in France and in Slovenia, and to quantify the consequence of the results of new imaging modality on the detection rate of abnormal metastases and recurrences of prostate cancer.Patients and methodsIn two centres (France/Slovenia), a survey of the number of nuclear medicine examinations in patients with prostate cancer was performed, covering 5 quarters of the year since the introduction of FCH. For each examination, the clinical and biological circumstances were recorded, as well as the detection of bone or soft tissue foci.ResultsSix hundred and eighty-eight nuclear medicine examinations were performed impatients with prostate cancer. Nuclear medicine examinations were performed for therapy monitoring and follow-up in 23% of cases. The number of FCH PET/CT grew rapidly between the 1st and 5th period of the observation (+220%), while the number of bone scintigraphies (BS) and fluoride(18F) PET/CTs decreased (−42% and −23% respectively). Fluorodeoxyglucose(18F) (FDG) PET/CT remained limited to few cases of castrate-resistant or metastatic prostate cancer in Paris. The proportion of negative results was significantly lower with FCH PET/CT (14%) than with BS (49%) or fluoride(18F) PET/CT (54%). For bone metastases, the detection rate was similar, but FCH PET/CT was performed on average at lower prostate-specific antigen (PSA) levels and was less frequently doubtful (4% vs. 28% for BS). FCH PET/CT also showed foci in prostatic bed (53% of cases) or in soft tissue (35% of cases).ConclusionsA rapid development of FCH PET/CT was observed in both centres and led to a higher detection rate of prostate cancer lesions.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Consequence of the introduction of routine FCH PET/CT imaging for patients with prostate cancer: a dual centre survey

Hodolič¹,

Michaud²,

Huchet³

et al. 2014

Radiology and Oncology

View full text Add to dashboard Cite

show abstract

“…Des études, dont un essai clinique prospectif pivot, ont montré son efficacité pour détecter cette dissémination fréquente [1]. D'autres radiopharmaceutiques sont également enregistrés et utilisés depuis plusieurs années dans cette indication : les bisphonates technétiés et le fluorure (18F) de sodium [2,3]. Contrairement à ces agents, la FCH est accumulée au niveau de la moelle osseuse et non pas de l'os cortical, mais aussi par les localisations cancéreuses dans les tissus mous : tumeur primitive, métastases ganglionnaires locorégionales et métas-tases à distance extrasquelettiques [4][5][6][7].…”

Section: Introductionunclassified

Effet du traitement par pegfilgrastim sur la fixation de la fluorocholine (18F) par la moelle osseuse

et al. 2012

Self Cite

View full text Add to dashboard Cite

Évolution de la demande des examens de médecine nucléaire pour cancer de la prostate depuis l’enregistrement de la fluorocholine (18F) : analyse sur deux ans à l’hôpital Tenon

Cited by 2 publications

References 32 publications

Consequence of the introduction of routine FCH PET/CT imaging for patients with prostate cancer: a dual centre survey

Consequence of the introduction of routine FCH PET/CT imaging for patients with prostate cancer: a dual centre survey

Effet du traitement par pegfilgrastim sur la fixation de la fluorocholine (18F) par la moelle osseuse

Contact Info

Product

Resources

About